Reimbursement For ESRD Drugs To Be Based On Average Acquisition Cost
This article was originally published in The Pink Sheet Daily
Executive Summary
The Centers for Medicare & Medicaid Services will base reimbursement for end-stage renal disease therapies in 2005 on the average acquisition cost
You may also be interested in...
CMS To Increase Flu Vaccine Administration Fees In Final Part B Rule
The Center for Medicare & Medicaid Services' final 2005 Physician Fee Schedule is understood to include a payment increase for administration of the flu vaccine to Medicare beneficiaries
Amgen EPO Claims Monitoring To Include Dosing Levels – CMS Draft Policy
Proposed revision would replace current policy of targeting physicians whose patients have average hematocrit levels over 37.5%. New policy would review erythropoietin claims with high hematocrit/hemoglobin levels and high doses.
Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.